Technical Analysis for MRSN - Mersana Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical MRSN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -2.75% | |
| Bollinger Band Squeeze | Range Contraction | -2.75% | |
| Narrow Range Bar | Range Contraction | -2.75% | |
| Inside Day | Range Contraction | -2.75% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2019
- Sector: Healthcare
- Industry: Biotechnology
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Medicine Biotechnology Cancer Immunology Cancers Chemotherapy Monoclonal Antibodies Antibody Drug Conjugates Adc
Medicine Biotechnology Cancer Immunology Cancers Chemotherapy Monoclonal Antibodies Antibody Drug Conjugates Adc
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRSN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 15.93 |
| 52 Week Low | 2.845 |
| Average Volume | 285,283 |
| 200-Day Moving Average | 5.274 |
| 50-Day Moving Average | 4.461 |
| 20-Day Moving Average | 4.0505 |
| 10-Day Moving Average | 3.978 |
| Average True Range | 0.2352 |
| ADX | 12.84 |
| +DI | 12.6716 |
| -DI | 18.0368 |
| Chandelier Exit (Long, 3 ATRs ) | 3.6944 |
| Chandelier Exit (Short, 3 ATRs ) | 4.5656 |
| Upper Bollinger Band | 4.2372 |
| Lower Bollinger Band | 3.8638 |
| Percent B (%b) | 0.07 |
| BandWidth | 9.218615 |
| MACD Line | -0.1046 |
| MACD Signal Line | -0.1196 |
| MACD Histogram | 0.015 |
| Fundamentals | Value |
|---|---|
| Market Cap | 88.35 Million |
| Num Shares | 22.7 Million |
| EPS | -16.23 |
| Price-to-Earnings (P/E) Ratio | -0.24 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.31 | ||||
| Resistance 3 (R3) | 4.35 | 4.24 | 4.24 | ||
| Resistance 2 (R2) | 4.24 | 4.14 | 4.23 | 4.22 | |
| Resistance 1 (R1) | 4.07 | 4.07 | 4.02 | 4.03 | 4.19 |
| Pivot Point | 3.96 | 3.96 | 3.94 | 3.95 | 3.96 |
| Support 1 (S1) | 3.79 | 3.86 | 3.74 | 3.75 | 3.59 |
| Support 2 (S2) | 3.68 | 3.79 | 3.67 | 3.56 | |
| Support 3 (S3) | 3.51 | 3.68 | 3.54 | ||
| Support 4 (S4) | 3.47 |
